91 related articles for article (PubMed ID: 8031507)
1. Effect of targeted erythrocytes coated with recombinant human interleukin 2 on T-lymphocyte proliferation in vitro.
Kirch HJ; Moyes RB; Chiarantini L; DeLoach JR
Biotechnol Appl Biochem; 1994 Jun; 19(3):331-40. PubMed ID: 8031507
[TBL] [Abstract][Full Text] [Related]
2. Synergistic actions of picibanil (OK-432) on recombinant interleukin-2 induction of tumor-infiltrating lymphocyte expansion, cytotoxicity, and phenotypic differentiation.
Lafreniere R; Borkenhagen K; Bryant LD; Ng E; Hayton S
J Biol Response Mod; 1990 Feb; 9(1):53-60. PubMed ID: 2181072
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
4. In vitro targeting of erythrocytes to cytotoxic T-cells by coupling of Thy-1.2 monoclonal antibody.
Chiarantini L; Droleskey R; Magnani M; DeLoach JR
Biotechnol Appl Biochem; 1992 Apr; 15(2):171-84. PubMed ID: 1586457
[TBL] [Abstract][Full Text] [Related]
5. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
6. Biological functions of recombinant human interleukin-2.
Liu XY; Yu JL; Zheng HD; Chen Y; Shen JF; Feng ZH; Chen ZC; You LF; Sun BH; Zhou YY
Chin J Biotechnol; 1991; 7(1):25-31. PubMed ID: 1773013
[TBL] [Abstract][Full Text] [Related]
7. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
9. Expression of high-affinity IL-4 receptors on murine tumour infiltrating lymphocytes and their up-regulation by IL-2.
Puri RK; Finbloom DS; Leland P; Mostowski H; Siegel JP
Immunology; 1990 Aug; 70(4):492-7. PubMed ID: 2203676
[TBL] [Abstract][Full Text] [Related]
10. Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.
Tsujitani S; Nakashima M; Watanabe T; Kaibara N; Koprowski H; Steplewski Z
Anticancer Res; 1995; 15(3):655-60. PubMed ID: 7645938
[TBL] [Abstract][Full Text] [Related]
11. T4 cell activation by immobilized phytohemagglutinin: differential capacity to induce IL-2 responsiveness and IL-2 production.
Vine JB; Geppert TD; Lipsky PE
J Immunol; 1988 Oct; 141(8):2593-600. PubMed ID: 2844904
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of new-type recombinant interleukin-2.
Feng XS; Zheng XJ; Si QS; Lin YL; Chang Y; Fan PF; Yu JL; Zhang SR; Liu XY
Zhongguo Yao Li Xue Bao; 1992 Sep; 13(5):435-8. PubMed ID: 1300048
[TBL] [Abstract][Full Text] [Related]
13. Recombinant IL 2 but not recombinant interferon-gamma stimulates both proliferation and IgM secretion in a Ly-1+ clone of neoplastic murine B cells (BCL1).
Brooks KH; Vitetta ES
J Immunol; 1986 Nov; 137(10):3205-10. PubMed ID: 2945863
[TBL] [Abstract][Full Text] [Related]
14. Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation.
Vyth-Dreese FA; Dellemijn TA; Frijhoff A; van Kooyk Y; Figdor CG
Eur J Immunol; 1993 Dec; 23(12):3292-9. PubMed ID: 7903074
[TBL] [Abstract][Full Text] [Related]
15. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.
Gajewski TF; Fitch FW
J Immunol; 1988 Jun; 140(12):4245-52. PubMed ID: 2967332
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 2 up-regulates its own production.
Hu J; Vaquero C; Huet S; Bernard A; Sterkers G
J Immunol; 1987 Dec; 139(12):4109-15. PubMed ID: 3121730
[TBL] [Abstract][Full Text] [Related]
17. Enhanced biological activity of human recombinant interleukin 2 coupled to mouse red blood cells as evaluated using the mouse Meth A sarcoma model.
Moyes RB; Kirch H; DeLoach JR
Biotechnol Appl Biochem; 1996 Feb; 23(1):29-36. PubMed ID: 8867894
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
19. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
